Neumora Therapeutics(US:NMRA)2025-11-06 12:05Financial Position - Neumora reported a cash position of $171.5 million as of September 30, 2025, expected to support operations into 2027[8]. - An additional $40 million in non-dilutive capital was drawn from the existing facility with K2 HealthVentures, strengthening the company's financial position[3]. - Total operating expenses for Q3 2025 were $57.7 million, down from $76.6 million in Q3 2024[11]. Research and Development - Research and development expenses for Q3 2025 were $40.5 million, down from $60.6 million in Q3 2024, primarily due to reduced clinical trial costs[8]. - Neumora announced class-leading data for NMRA-215, a highly brain-penetrant NLRP3 inhibitor, with plans to initiate a Phase 1 study in Q1 2026[1][4]. - The company is advancing Phase 1 studies for NMRA-861 and NMRA-898, with a comprehensive update expected by mid-2026[1][5]. - Data from the Phase 1b study of NMRA-511 in Alzheimer's disease agitation is expected to be reported around the end of 2025[1][6]. - Enrollment is ongoing in the Phase 3 KOASTAL program for navacaprant in major depressive disorder, with topline data expected in 1H 2026[1][7]. Expenses and Losses - General and administrative expenses decreased to $12.2 million in Q3 2025 from $16.0 million in Q3 2024, attributed to lower consulting and personnel costs[8]. - The net loss for Q3 2025 was $56.8 million, compared to a net loss of $72.5 million for the same period in 2024[8].